Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of livmoniplimab alone and with budigalimab in advanced or metastatic solid tumors
jRCT2080224727Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of livmoniplimab and budigalimab in Nonhematologic neoplasms, pancreatic adenocarcinoma (PDAC), transitional cell carcinoma (TCC) and 5 more (15 cohorts), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability, Pharmacokinetics and 1 more. Started Jun 2019; status: completed.
02
Drugs
livmoniplimabbudigalimab
03
Conditions
Nonhematologic neoplasmspancreatic adenocarcinoma (PDAC)transitional cell carcinoma (TCC)hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080224727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224727.